AVITA Medical to Announce First Quarter 2022 Financial Results
29 April 2022 - 6:01AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announced today that it will
release its first quarter 2022 financial results on Thursday, May
12, 2022. In conjunction with such release, the Company plans to
host a conference call and webcast that day at 1:30 p.m. Pacific
Time / 4:30 p.m. Eastern Time (Friday, May 13, 2022 at 6:30 a.m.
Australian Eastern Standard Time) to discuss its financial results
and recent highlights.
Interested parties may access the live call via telephone by
dialing (833) 614-1538 for domestic callers or (706) 634-6548 for
international callers, using conference ID: 7569924. The live
webinar of the call may be accessed by visiting the Events section
of the Company’s website at ir.avitamedical.com. A replay of the
webinar will be available on the Company’s website shortly after
the conclusion of the call.
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
ABOUT AVITA MEDICAL, INC.AVITA Medical is a
regenerative medicine company with a technology platform positioned
to address unmet medical needs in burns, chronic wounds, and
aesthetics indications. AVITA Medical’s patented and proprietary
collection and application technology provides innovative treatment
solutions derived from the regenerative properties of a patient’s
own skin. The medical devices work by preparing a RES® REGENERATIVE
EPIDERMAL SUSPENSION, an autologous suspension comprised of the
patient’s skin cells necessary to regenerate natural healthy
epidermis. This autologous suspension is then sprayed onto the
areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns. The RECELL System is used to
prepare Spray-On Skin™ Cells using a small amount of a patient’s
own skin, providing a new way to treat severe burns, while
significantly reducing the amount of donor skin required. The
RECELL System is designed to be used at the point of care alone or
in combination with autografts depending on the depth of the burn
injury. Compelling data from randomized, controlled clinical trials
conducted at major U.S. burn centers and real-world use in more
than 10,000 patients globally reinforce that the RECELL System is a
significant advancement over the current standard of care for burn
patients and offers benefits in clinical outcomes and cost savings.
Healthcare professionals should read the INSTRUCTIONS FOR USE -
RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings, and precautions.In international
markets, our products are marketed under the RECELL System brand to
promote skin healing in a wide range of applications including
burns, chronic wounds, and aesthetics. The RECELL System is
TGA-registered in Australia and received CE-mark approval in
Europe. To learn more, visit www.avitamedical.com.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy CurranPhone
+1-615-414-8668christycurran@sambrown.comO.U.S.
MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61
(0)411 402 737 rudim@monsoon.com.au |
InvestorsICR WestwickeCaroline CornerPhone
+1-415-202-5678 caroline.corner@westwicke.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024